4
CORE PLATFORM
CORE
PLA
TFO
RM
BACKGROUND
SingHealth Clinical Pharmacology aims to provide services and collaborative support to clinicians, clinician scientists and researchers from healthcare institutions, pharmaceutical companies and academia.
We o�er services to support pharma-sponsored as well as investigator-initiated clinical trials (early phase I and II). This includes consultation on clinical study design, generating bio-analytical, pharmacokinetics and pharmacogenomics data and analysis of results.
We also strive to understand the pharmacokinetics and pharmacodynamics of therapeutic agents, and their in�uence on clinical outcomes in Asian populations. In addition, we also o�er therapeutic drug monitoring services. In all, this will lead to the development of better treatment regimens and strategies and in turn, promote safer and more e�ective use of medications.
CORE STRENGTHS
Our team of dedicated scientists support a range of services at all stages of drug development and personalised delivery of therapeutics into the clinics. The facility is equipped with cutting-edge instrumentation, including:
AB SCIEX 5500 QTRAP LC-MS/MS System
Shimadzu Prominence LC
Applied Biosystems 7500 FAST Real-Time PCR
Our suite of software for in-depth analysis includes:
NONMEM® including PDx-POP
Phoenix WinNonlin®
Graphpad Prism®
SigmaPlot®
SAS®
R-software
DNASTAR Lasergene® Genomic Suite
Qiagen PyroMark Q24
Perkin Elmer EnSpire Multimode Microplate Analyzer
OUR PORTFOLIO
Quantitative bio-analytical services
Development and validation ofbio-analytical assays
Therapeutic drug monitoring
Metabolite identi�cation and pro�ling
Pharmacokinetics/Pharmacodynamics (PK/PD) modelling and simulation
Design of early phase clinical trials
Bioavailability and bioequivalence studies
Preclinical and clinical pharmacokinetics analyses and modelling
In vivo characterization of drug-drug interactions
Population PK modelling with NONMEM®
Non-compartmental analysis with Phoenix WinNonlin
Statistical analysis with Prism, R-software and SAS
Preclinical enzyme kinetics/inhibition and transporters studies
Generation of study reports
The facility is geared towards compliance with international GLP guidelines and will incorporate accredited units in the near future to support drug discovery and clinical development programmes.
SingHealth Clinical Pharmacology will continue to build on their core strengths to distinguish themselves in a competitive market and to bring value to your project.
Pharmacogenomics
DNA extraction from various biological matrices
DNA sequencing & SNP discovery
Genotype-phenotype association analysis
Pharmacogenetics-based functional studies in in vitro and in vivo models
Pharmacokinetics/pharmacogenomics association analysis
Pharmacology-related knowledgeand training
Advice on grant applications pertaining to clinical pharmacology of drugs
Support the training of clinicians and clinician-scientists on the relevance of clinical pharmacology in the management of patients
Training of academic interns
Storage of clinical trial samples
Available in our facility are 4°C fridges, -20/80°C freezers and liquid nitrogen storage tanks to store your clinical trials’ plasma and tissue samples; and blood components.
SingHealth Clinical
Pharmacology
Expertise in advanced PK/PD
modeling
Extensive translational
research experience
Expertise in development &
validation of GLP bio-analytical
assays
Experience in early phase clinical trial
design
Close collaboration with SingHealth Investigational Medicine Unit
E�cient project management &
clinical pharmacology
support
The content is correct at the time of printing.©2015 SingHealth O�ce of Research. All rights reserved.
SingHealth Clinical Pharmacology
20 College Road,The Academia, Discovery Tower, Level 8Singapore 169856
Tel: (+65) 6576 7096Email: [email protected]
DIRECTOR’S BIO
Prof Balram Chowbay is Principal Investigator of the Clinical Pharmacology Laboratory in National Cancer Centre Singapore and Director of SingHealth Clinical Pharmacology. He is head of the Laboratory Science Coordination Core of Academic of Medical Research Institution and a visiting scientist at KK Women's and Children's Hospital. He is also an Adjunct Professor at O�ce of Clinical Sciences at Duke-NUS Graduate Medical School Singapore and School of Chemical and Biological Engineering at Nanyang Technological University.
Prof Balram has been actively involved in clinical pharmacology research and early phase clinical trials of anti-cancer agents. His research has largely focused on the applications of pharmacokinetics and pharmacodynamics principles to optimize individualized dosage regimens. His contributions are particularly important in the context of Asian populations.
